These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 9053487

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. NICE approves Taxol for ovarian cancer.
    Kmietowicz Z.
    BMJ; 2000 May 13; 320(7245):1293. PubMed ID: 10807610
    [No Abstract] [Full Text] [Related]

  • 23. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
    Leighl NB, Shepherd FA, Kwong R, Burkes RL, Feld R, Goodwin PJ.
    J Clin Oncol; 2002 Mar 01; 20(5):1344-52. PubMed ID: 11870178
    [Abstract] [Full Text] [Related]

  • 24. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF.
    J Natl Compr Canc Netw; 2004 Sep 01; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [Abstract] [Full Text] [Related]

  • 25. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
    Smith HJ, Walters Haygood CL, Arend RC, Leath CA, Straughn JM.
    Gynecol Oncol; 2015 Oct 01; 139(1):59-62. PubMed ID: 26303225
    [Abstract] [Full Text] [Related]

  • 26. ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.
    Foote J, Secord AA, Liang M, Cohn DE, Jewell E, Havrilesky LJ.
    J Oncol Pract; 2017 Dec 01; 13(12):e1030-e1039. PubMed ID: 29016225
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.
    Dalton HJ, Yu X, Hu L, Kapp DS, Benjamin I, Monk BJ, Chan JK.
    Gynecol Oncol; 2012 Feb 01; 124(2):199-204. PubMed ID: 22055763
    [Abstract] [Full Text] [Related]

  • 29. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G.
    J Clin Oncol; 1999 Oct 01; 17(10):3082-90. PubMed ID: 10506603
    [Abstract] [Full Text] [Related]

  • 30. Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Havrilesky LJ, Pokrzywinski R, Revicki D, Higgins RV, Nycum LR, Kohler MF, Berchuck A, Myers ER, Secord AA.
    Cancer; 2012 Jan 15; 118(2):386-91. PubMed ID: 21598242
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
    Evans WK.
    Oncology (Williston Park); 1998 Mar 15; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR.
    Clin Ther; 2012 Jul 15; 34(7):1531-43. PubMed ID: 22742885
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L, Jovtis SL, Mickiewicz E, Temperley G, Rondinón M, Blajman C, Cóppola FS, Lewi D, Cazap E, Breier S, Fasce H, Fein L, Polera J, Triguboff E, Uranga G, Pasccón G, Luchina AM, Martínez CA, Politi PM, Rubio G, Alvarez AM.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.
    Thigpen T, Vance RB, McGuire WP, Hoskins WJ, Brady M.
    Semin Oncol; 1995 Dec 15; 22(6 Suppl 14):23-31. PubMed ID: 8553080
    [Abstract] [Full Text] [Related]

  • 38. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
    Alba E, Ciruelos E, López R, López-Vega JM, Lluch A, Martín M, Muñoz M, Sánchez-Rovira P, Seguí MÁ, Liria MR, Pérez-Alcántara F.
    Expert Rev Pharmacoecon Outcomes Res; 2013 Jun 15; 13(3):381-91. PubMed ID: 23534988
    [Abstract] [Full Text] [Related]

  • 39. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.
    Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, Leighl NB.
    J Clin Oncol; 2014 Apr 01; 32(10):1012-9. PubMed ID: 24567430
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.